Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1800 participants.
Also called NCT06736574
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,800 participants
- Sponsor
- Registry
-
NCT06736574 -
2024-519219-32-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, China, France, Germany, Greece, Italy, Poland, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06736574. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-19 (actual); primary completion 2027-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
- Acronym
- COMET-HF
- Condition
- Heart Failure
- Intervention (Drug)
- Omecamtiv Mecarbil (OM)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Cytokinetics
Record details
- Record id
cardio:ct-nct06736574- Content hash
1e6587e3d0161071fdfa0fdfffb2be6ced215a706719595b46619335429e9e67